- New Clinical Data on ARO-RAGE Show Continued Dose Response with Single Inhaled Dose of 184 mg Achieving Mean Knockdown of 90% and Max of 95% - Adipose Delivery Platform Achieved Single Dose Target Gene Silencing of Greater than 90% with Six Months of Duration in Non-human Primates - Improved

- 44-48% Mean Reductions in LDL-C Achieved on Top of Continued Standard of Care - Phase 3 Planning is Ongoing PASADENA, Calif. --(BUSINESS WIRE)--May 23, 2023-- Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today presented interim data from the ongoing Phase 2 GATEWAY clinical study of ARO-ANG3,

- Primary Study Completion Anticipated in the Second Quarter of 2024 PASADENA, Calif. --(BUSINESS WIRE)--May 16, 2023-- Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it has completed enrollment of its global Phase 3 clinical trial (PALISADE) evaluating ARO-APOC3 for the

PASADENA, Calif. --(BUSINESS WIRE)--May 15, 2023-- Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it is scheduled to participate in the following upcoming investor events: 2023 RBC Capital Markets Global Healthcare Conference – May 17, 2023 Type: Fireside chat presentation 91

- Conference Call and Webcast Today, May 2, 2023 at 4:30 p.m. ET PASADENA, Calif. --(BUSINESS WIRE)--May 2, 2023-- Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced financial results for its fiscal second quarter ended March 31, 2023 . The company is hosting a conference call today,

- Interim Results from Ongoing ARO-RAGE Phase 1/2 Study Demonstrate up to 90% Serum sRAGE Reduction with Mean Maximum Reduction of 80% after Two Doses - Further Data to be Presented at Upcoming R&D Day PASADENA, Calif. --(BUSINESS WIRE)--Apr. 25, 2023-- Arrowhead Pharmaceuticals Inc.

PASADENA, Calif. --(BUSINESS WIRE)--Apr. 18, 2023-- Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it will host a webcast and conference call on May 2, 2023 , at 4:30 p.m. ET to discuss its financial results for the fiscal 2023 second quarter ended March 31, 2023 .

- Event to include presentations on cardiometabolic, pulmonary, and newly announced central nervous system pipeline programs PASADENA, Calif. --(BUSINESS WIRE)--Apr. 12, 2023-- Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it will host a Research & Development (R&D) Day on June

PASADENA, Calif. --(BUSINESS WIRE)--Apr. 4, 2023-- Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that the first patient has been dosed in Takeda’s (TSE:4502/NYSE:TAK) Phase 3 REDWOOD clinical study of fazirsiran (TAK-999/ARO-AAT) for the treatment of alpha-1 antitrypsin deficiency

PASADENA, Calif. --(BUSINESS WIRE)--Apr. 3, 2023-- Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it earned a $30 million milestone payment from GSK (LSE/NYSE: GSK) following the start of GSK’s Phase 2b trial of GSK4532990, formerly called ARO-HSD, an investigational RNA